AR123802A1 - ANGIOEDEMA TREATMENTS - Google Patents
ANGIOEDEMA TREATMENTSInfo
- Publication number
- AR123802A1 AR123802A1 ARP210102853A ARP210102853A AR123802A1 AR 123802 A1 AR123802 A1 AR 123802A1 AR P210102853 A ARP210102853 A AR P210102853A AR P210102853 A ARP210102853 A AR P210102853A AR 123802 A1 AR123802 A1 AR 123802A1
- Authority
- AR
- Argentina
- Prior art keywords
- angioedema
- treatments
- compound
- formula
- solvate
- Prior art date
Links
- 208000028185 Angioedema Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 2: El compuesto de fórmula (A) (o una sal y/o solvato farmacéuticamente aceptable de este) para uso en un método para el tratamiento profiláctico de un angioedema mediado por bradicinina que comprende: la administración oral de un compuesto fórmula A (o una sal y/o solvato farmacéuticamente aceptable de este) a un paciente que lo necesita, caracterizado porque el compuesto de fórmula A es, como se muestra a continuación.Claim 2: The compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof) for use in a method for the prophylactic treatment of bradykinin-mediated angioedema comprising: oral administration of a compound formula A ( or a pharmaceutically acceptable salt and/or solvate thereof) to a patient in need thereof, characterized in that the compound of formula A is, as shown below.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063092014P | 2020-10-15 | 2020-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123802A1 true AR123802A1 (en) | 2023-01-11 |
Family
ID=85131252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102853A AR123802A1 (en) | 2020-10-15 | 2021-10-15 | ANGIOEDEMA TREATMENTS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123802A1 (en) |
-
2021
- 2021-10-15 AR ARP210102853A patent/AR123802A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119158A1 (en) | HEREDITARY ANGIOEDEMA TREATMENTS | |
| CO2022013777A2 (en) | Use of agents for the treatment of respiratory conditions | |
| CO2020013600A2 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2019012884A (en) | COMBINATION THERAPY. | |
| MX2024002538A (en) | Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma. | |
| PE20170302A1 (en) | USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE | |
| CL2021003032A1 (en) | Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor. | |
| ES2570401T3 (en) | Methods of treatment using single doses of oritavancin | |
| CL2022003039A1 (en) | il4i1 inhibitors and methods of use. | |
| MX2021014161A (en) | Methods of treating sjãgren's syndrome using a bruton's tyrosine kinase inhibitor. | |
| AR119159A1 (en) | ANGIOEDEMA TREATMENTS | |
| CL2022000781A1 (en) | Medicinal cognitive treatments | |
| CO2022015891A2 (en) | Co-administration of mirdametinib and lifirafenib for use in the treatment of cancers | |
| MX2022016406A (en) | METHODS FOR TREATING CANCER OR VON-HIPPEL LINDAU DISEASE USING A COMBINATION OF A HIF-2 ALPHA INHIBITOR AND LENVATINIB. | |
| MX2025002228A (en) | Methods for the treatment or prophylaxis of endometriosis | |
| CL2022000320A1 (en) | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | |
| AR123802A1 (en) | ANGIOEDEMA TREATMENTS | |
| AR131842A1 (en) | METHODS FOR TREATING GLIOMAS | |
| CO2023017669A2 (en) | Advantageous anti-hcv combination therapy | |
| AR131503A1 (en) | Spirocyclic HPK1 antagonists and their uses | |
| MX2023013514A (en) | METHODS FOR TREATING INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME. | |
| AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
| CL2024003598A1 (en) | Piperazine derivatives useful in hiv therapy. | |
| CO2023010910A2 (en) | Prader-willi syndrome treatments | |
| AR132852A1 (en) | COMBITHERAPY TO TREAT CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |